CoChat

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Purpose: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose. Patients and Methods: Subjects with ccRCC and progressive disease after at least 2 prior therapies that included VEGF and immune checkpoint inhibitors were progressively enrolled into dose-escalation cohorts of ARO-HIF2 administered intravenously at 225, 525, or 1,050 mg weekly. Results: Twenty-six subjects received ARO-HIF2. The most common treatment emergent adverse events (AE) irrespective of causality were fatigue (50.0%), dizziness (26.9%), dyspnea (23.1%), and nausea (23.1%). Four subjects (15.4%) had treatment-related serious AEs. AEs of special interest included neuropathy, hypoxia, and dyspnea. ARO-HIF2 was almost completely cleared from plasma circulation within 48 hours with minimal renal clearance. Reductions in HIF2α were observed between pre- and post-dosing tumor biopsies, but the magnitude was quite variable. The objective response rate was 7.7% and the disease control rate was 38.5%. Responses were accompanied by ARO-HIF2 uptake in tumor cells, HIF2α downregulation, as well as rapid suppression of tumor produced erythropoietin (EPO) in a patient with paraneoplastic polycythemia. Conclusions: ARO-HIF2 downregulated HIF2α in advanced ccRCC—inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3029

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Summary of treatment duration with tumor response in the three cohorts'. Cohort 1 (225 mg ARO-HIF2), Cohort 2 (525 mg ARO-HIF2), and Cohort 3 (1050 mg ARO-HIF2). Abbreviations: A, Subject A; B, Subject B; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 1. Summary of treatment duration with tumor response in the three cohorts'. Cohort 1 (225 mg ARO-HIF2), Cohort 2 (525 mg ARO-HIF2), and Cohort 3 (1050 mg ARO-HIF2). Abbreviations: A, Subject A; B, Subject B; PD, progressive disease; PR, partial response; SD, stable disease.CC BY-NC-ND · PubMed Central
Figure 2. Waterfall plot of best sum of diameters percentage of change for target lesions. Among the 6 subjects with a percentage of change in target lesion size in the SD range (between −30% and +20%) who had PD, 4 subjects had PD of a non-target lesion, 1 subject had a new lesion, and 1 subject had both PD in a non-target lesion and a new lesion. Abbreviations: A, Subject A; B, Subject B; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 2. Waterfall plot of best sum of diameters percentage of change for target lesions. Among the 6 subjects with a percentage of change in target lesion size in the SD range (between −30% and +20%) who had PD, 4 subjects had PD of a non-target lesion, 1 subject had a new lesion, and 1 subject had both PD in a non-target lesion and a new lesion. Abbreviations: A, Subject A; B, Subject B; PD, progressive disease; PR, partial response; SD, stable disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Wong, 2019, Optimizing the potency and dosing design for ARO-HIF2: an RNAi therapeutic for clear cell renal cell carcinoma [abstract]

Cited by

See all 29

Metadata

Authors
Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., Gamelin, E., & Tannir, N. M.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Comprehensive Cancer Centers of Nevada (US)
  • Vanderbilt University (US)
  • University of Colorado Cancer Center (US)
  • Arrowhead Pharmaceuticals (United States) (US)
  • 6Gamelin Biopharma Consulting, Wilmington, Delaware.
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Brugarolas, James
  • Tannir, Nizar M.
Venue
Clinical Cancer Research
Published
2024-04-23
Volume
30
Issue
11
Pages
2402-2411
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4395036823
Cited by
25
References
30
Citations by year
2026: 8 · 2025: 15 · 2024: 2
FWCI
7.22
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P50CA196516)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
HIF-2α, clear cell renal cell carcinoma, siRNA, RNA interference, hypoxia-inducible factor, pharmacokinetics, safety and tolerability, dose escalation, erythropoietin, neurotoxicity, targeted cancer therapy
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, RNA Interference, RNA, Small Interfering, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3029
The paper
Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., Gamelin, E., & Tannir, N. M. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.